Skip to content
Life Sciences Series C Founded 2018

Huida

Developer of gene therapies for the treatment of multiple disease conditions. The company is focusing on gene therapy drugs such as gene replacement and gene editing for rare single-gene genetic diseases. The company's pipeline includes HG-001, HG-202, HG-004, HG-203 for neurodegenerative diseases, visual impairment, and hearing impairment. Founded in 2018, headquartered in Pudong, China. The company has raised…

📍 Pudong, China · Genomics,

Funding snapshot

Last roundSeries C
Amount$19M
Date12 May 2022
Total raised$19M
Team size28

About

Developer of gene therapies for the treatment of multiple disease conditions. The company is focusing on gene therapy drugs such as gene replacement and gene editing for rare single-gene genetic diseases. The company's pipeline includes HG-001, HG-202, HG-004, HG-203 for neurodegenerative diseases, visual impairment, and hearing impairment. Founded in 2018, headquartered in Pudong, China. The company has raised $18.5M in funding at the series c stage. The company operates in the Genomics sector with additional focus on Neurology. Its business model centers on Diversified. Founded in 2018, headquartered in Pudong, China. The company has raised $18.5M at the Series C stage. Backed by investors including Kunlun Capital, CD Capital, Sherpa Venture Capital, WuXi AppTec, HM Venture Partners and others.

Business model

Neurology > Drugs > Neurodegenerative > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Kunlun Capital CD Capital Sherpa Venture Capital WuXi AppTec HM Venture Partners Yahui Capital Alwin Capital

Latest coverage

No articles yet.

Raising like Huida?

Analyze your pitch deck before your next raise.

Analyze My Deck →